EUVIMEDEUVIMED entdecken
Crossref

Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval

Mohamed A Kamal, Samit Ganguly, Ananth Kadambi, Patrick F Smith

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3357 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Mohamed A Kamal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Tarrytown, New York, USA. Hauptthemen laut MEDLINE: Drug Development, Drug Approval, Clinical Trials as Topic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentDrug ApprovalClinical Trials as TopicHumansUnited States Food and Drug AdministrationUnited StatesModels, Biological

Autor:innen und Institutionen

  • Regeneron Pharmaceuticals, Tarrytown, New York, USA.
  • Certara, Princeton, New Jersey, USA.

Zitieren

APA

Kamal, M. A., Ganguly, S., Kadambi, A., & Smith, P. F. (2024). Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3357

Vancouver

Kamal MA, Ganguly S, Kadambi A, Smith PF. Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3357

BibTeX
@article{Kamal2024,
  author = {Kamal, Mohamed A and Ganguly, Samit and Kadambi, Ananth and Smith, Patrick F},
  title = {Extended Model‐Informed Drug Development: Beyond Clinical Trials and Regulatory Approval},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3357}
}
Kostenlos starten →